Completed

Study of Talabostat and Cisplatin in Advanced Melanoma

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Melanoma+9

+ Neoplasms

+ Neoplasms by Histologic Type

Over 18 Years
+14 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
See protocol details

Summary

Principal SponsorPoint Therapeutics
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

The purpose of this study is to assess the antitumor activity and safety of the combination of talabostat and cisplatin in patients with metastatic melanoma.

Official TitleStudy of Talabostat and Cisplatin in Advanced Melanoma
NCT00083252
Principal SponsorPoint Therapeutics
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

MelanomaNeoplasmsNeoplasms by Histologic TypeNeoplasms by SiteNeoplasms, Germ Cell and EmbryonalNeoplasms, Nerve TissueSkin DiseasesSkin NeoplasmsSkin and Connective Tissue DiseasesNeuroectodermal TumorsNevi and MelanomasNeuroendocrine Tumors

Criteria

5 inclusion criteria required to participate
Histologically or cytologically confirmed melanoma that is metastatic (unresectable Stage IV per AJCC 2002)
Patients with measurable disease defined as at least one measurable index lesion with clearly defined margins
ECOG Performance Status of 0, 1, or 2
Expected survival ≥12 weeks
Show More Criteria
9 exclusion criteria prevent from participating
More than 1 prior chemotherapy or biotherapy regimen for metastatic melanoma
Radiation therapy to >50% of the bone marrow. Patients must not have had prior radiotherapy to index lesions unless they have clearly progressive disease in this site or there is measurable disease outside the area of prior radiation.
Clinically significant laboratory abnormalities
Symptomatic CNS metastases
Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 13 locations

Suspended

University of Arkansas Medical Sciences

Little Rock, United StatesOpen University of Arkansas Medical Sciences in Google Maps
Suspended

Cancer Institute Medical Group, Inc.

Santa Monica, United States
Suspended

University of Colorado Health Sciences Center

Aurora, United States
Suspended

Cancer Center of Florida

Ocoee, United States
Completed13 Study Centers